Interleukin-2, interferon alpha, capecitabine and vinblastin for treatment of metastatic renal cell carcinoma: a multicenter study.

Trial Profile

Interleukin-2, interferon alpha, capecitabine and vinblastin for treatment of metastatic renal cell carcinoma: a multicenter study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capecitabine; Interferon alpha; Interleukin-2; Vinblastine
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top